All Articles in: Boston Scientific

U.S. FDA Approval for Boston Scientific’s Precision Montage™ MRI Spinal Cord Stimulator SystemMay 20, 2016

Full-Body MRI access expands Spinal Cord Stimulation offering and brings customized therapy to more patients suffering from chronic pain

Posted in: ,


Boston Scientific Launches Single-Use Flexible UreteroscopeJanuary 12, 2016

Ureteroscopes are used 4600 times a day to examine the urinary tract. Boston Scientific is claiming a first with its new disposable offering, which does sound like a game changer

Posted in: , , ,


FDA Approval And CE Mark for Boston Scientific’s DVT CatheterDecember 1, 2015

ZelanteDVT catheter is the first AngioJet catheter designed specifically to treat DVT

Posted in: , ,


Boston Scientific Targets Endoscopic Ultrasound Leadership with Xlumena BuyApril 2, 2015

Boston Scientific Corporation is to acquire Xlumena, Inc., developer of Endoscopic Ultrasound-guided transluminal drainage devices

Posted in: , ,


FDA and CE Mark Approval for Boston Scientific’s Thinner S-ICD SystemMarch 20, 2015

Boston Scientific will be hoping its new S-ICD will prove popular based on its advantages over conventionally placed leads

Posted in: , ,


FDA Approves Boston’s WATCHMAN™ Left Atrial Appendage Closure DeviceMarch 16, 2015

First-Of-Its-Kind alternative to long-term Warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation

Posted in: , , , ,


Launch and First Implant of Boston Scientific’s Long-Lasting ICDFebruary 3, 2015

The new Extended Longevity ICDs, featuring EnduraLife battery technology promise almost twelve years

Posted in: , ,


Retrospective Study Says Boston’s Spinal Cord Stimulator Works at 12 MonthsDecember 12, 2014

Whatever the value of retrospective data, Boston Scientific is touting results that make a solid case for its Precision Spectra spinal cord stimulator system

Posted in: , ,


Boston Scientific SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance EndpointsNovember 20, 2014

Boston Scientific reports that its SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in the first successful U.S. pivotal trial of a bioabsorbable polymer stent.

Posted in: , , ,


CE Mark for Boston’s Pacemaker Opens MRI Conditionality OptionsOctober 17, 2014

When implanted with Boston Scientific’s INGEVITY™ leads, Boston Scientific’s ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems.

Posted in: , ,


Third Time Lucky as FDA Panel Votes Yes to WATCHMAN™ LAA DeviceOctober 9, 2014

Expert Panel review has culminateded in a vote in favour of Boston Scientific Corporation’s WATCHMAN™ Left Atrial Appendage Closure Device.

Posted in: , , ,


Tangled Web Sees ICD Inventor Awarded $309 Million for nowSeptember 26, 2014

The family of the man who helped invent the ICD has been awarded $309 million against Boston Scientific, although appeals loom.

Posted in: , , , ,


Vagus Nerve Stimulation Study Misses Primary Efficacy Endpoint, But QOL ImprovedSeptember 1, 2014

It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.

Posted in: , ,


Boston Scientific and ASAHI INTECC Join Forces on FFR Wire ProjectAugust 19, 2014

Sounds like a plan. Combine the offerings of one of the Cardiovascular big boys with wire forming company’s expertise and FFR technology is likely to benefit.

Posted in: , ,


CE Mark for Boston Scientific’s Agent™ Drug-Coated Coronary BalloonJuly 30, 2014

Boston Scientific’s Agent™ Paclitaxel-Coated PTCA Balloon Catheter has gained CE mark approval and will now be launched in Europe.

Posted in: , ,


FDA Approves Boston Scientific’s REBEL™ Coronary StentJuly 22, 2014

U.S. FDA approval of REBEL™ Platinum Chromium Coronary Stent brings the benefits of modern stent architecture to patients not suitable for drug eluting variants.

Posted in: , ,


<< Previous Articles